

Serial No. 10/644,308


REMARKS

In response to the Office Action mailed 18 August 2005,
Applicant hereby elects the following species:

1. . . . where the method comprises administering a dendritic cell expansion agent.
2. . . . and where the method further comprises not administering a CD40 agonist post-immunization.
3. . . . where the dendritic cell maturation agent is type I interferon.
4. . . . where the species of rodent is mouse.
5. . . . where the mouse is BALB/c.

The claims that read on the species elected above include claims 1-3, 6, 7, 9, 10, 11 and 13.

Respectfully submitted,

By 
Kirk Baumeister
Reg. No. 33,833

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
Tel.: 610.240.8465
Fax: 610.651.6940
Dated: 13 September 2005